SentiBioLogo.jpg
Senti Bio to Participate in Upcoming Investor Conferences
September 03, 2024 08:15 ET | Senti Biosciences, Inc.
Senti Bio will participate in two upcoming investor conferences in September.
cambrium-logo-black-1500px (5).png
Cambrium Secures €8 Million in Seed Funding to Commercialize New Class of Performance Molecules
October 31, 2023 07:00 ET | Cambrium GmbH
Synthetic biology startup Cambrium announces €8 Million in Seed financing, led by Essential Capital, along with SNR, Valor Equity Partners, and HOF Capital
Synlogic_Logo_Blue.png
Synlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference
May 24, 2023 06:35 ET | Synlogic, Inc.
CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced its planned presentations at...
Synlogic_Logo_Blue.png
Synlogic to Present at the Jefferies Global Healthcare Conference
May 23, 2023 06:50 ET | Synlogic, Inc.
CAMBRIDGE, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B....
Synlogic_Logo_Blue.png
Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023 06:50 ET | Synlogic, Inc.
- Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – - Recent milestones include receipt of Rare Pediatric and Orphan Drug Designations from the FDA, and...
Synlogic_Logo_Blue.png
Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria
May 09, 2023 06:50 ET | Synlogic, Inc.
CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug...
Synlogic_Logo_Blue.png
Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
March 29, 2023 06:40 ET | Synlogic, Inc.
– Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934 for PKU and SYNB1353 for homocystinuria (HCU)...
Synlogic_Logo_Blue.png
Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria
March 28, 2023 06:52 ET | Synlogic, Inc.
CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the European Medicines...
Synlogic_Logo_Blue.png
Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
March 20, 2023 06:55 ET | Synlogic, Inc.
CAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, announced that positive data from the...
Synlogic_Logo_Blue.png
Synlogic to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 08, 2023 07:00 ET | Synlogic, Inc.
CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B....